experience in the United States of America and Japan shows that the strongest incentive for industry to invest in the development and marketing of orphan medicinal products is where there is a prospect of obtaining market exclusivity for a certain number of years during which part of the investment might be recovered; data protection under Article 4(8)(a)(iii) of Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products(4) is not a sufficient incentive for that purpose; Member States acting independently cannot introduce such a measure without a Community dimension as such a provision would be contradictory to Directive 65/65/EEC; if such measures were adopted in an uncoordinated manner by the Member States, this would create obstacles to intra-Community trade, leading to distortions of competition and running counter to the single market; market exclusivity should however be limited to the therapeutic indication for which orphan medicinal product designation has been obtained, without prejudice to existing intellectual property rights; in the interest of patients, the market exclusivity granted to an orphan medicinal product should not prevent the marketing of a similar medicinal product which could be of significant benefit to those affected by the condition;
Recital 8, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…
Judgment of the General Court (Sixth Chamber), 22 January 2015. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines AgencDecision
In support of their interpretation of Article 8(1) and (3) of Regulation No 141/2000, the applicants refer to the objectives pursued by that article, namely the provision of an incentive for investment in the form of a single ten-year …
22 Jan 2015 · 62012TJ0140
Judgment of the General Court (Ninth Chamber) of 26 January 2022. Mylan IRE Healthcare Ltd v European Commission.Decision
As is apparent from recital 8 of Regulation No 141/2000, that regulation nevertheless seeks to circumscribe that period of exclusivity in order not to prejudice existing intellectual property rights and, in the interests of patients, not …
26 Jan 2022 · 62016TJ0303
Judgment of the Court (Sixth Chamber) of 3 March 2016. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA).Decision
It should be recalled in that connection that, in order to provide the pharmaceutical industry with an incentive to sponsor the research, development and marketing of orphan medicinal products, Regulation No 141/2000 offers the sponsors of …
3 Mar 2016 · 62015CJ0138
Opinion of Advocate General Hogan delivered on 11 September 2019. PTC Therapeutics International Ltd v European Medicines Agency.Decision
The 8th recital to the regulation proceeds to state that experience in both the United States of America and Japan has shown that ‘the strongest incentive for industry to invest in the development and marketing of orphan medicinal …
11 Sep 2019 · 62018CC0175
Opinion of Advocate General Emiliou delivered on 11 July 2024. Mylan IRE Healthcare Ltd v European Commission.Decision
It is true that, rather puzzlingly, recital 8 of Regulation No 141/2000, refers to significant benefit although the derogation from the market exclusivity (to which issue that recital relates) relies on the concept of clinical superiority. …
11 Jul 2024 · 62022CC0237
Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…4Law
- celex=31965L0065
- celex=31993L0039
- num:eu=1965/65